Valgan (Valganciclovir) 450 mg
Valgan is a high-bioavailability antiviral medication. Active ingredient: Valganciclovir (450 mg).
Manufacturer: Cipla (India). Generic equivalent of Valcyte.
The "Prodrug" Advantage:
Valgan is a prodrug of ganciclovir. After oral administration, it is rapidly converted into ganciclovir in the body. Its absorption is nearly as effective as intravenous (IV) infusion, allowing patients to treat serious CMV infections at home with tablets instead of staying in the hospital for IV therapy.
✅ Convenience: Significantly reduces the "pill burden" compared to oral ganciclovir capsules.
Indicated for:
- CMV Retinitis: Treatment in patients with Acquired Immunodeficiency Syndrome (AIDS).
- CMV Prophylaxis: Prevention of Cytomegalovirus disease in kidney, heart, and kidney-pancreas transplant recipients.
Strength: 450 mg tablet.
Standard Adult Regimens:
- Induction: 900 mg (2 tablets) twice daily for 21 days.
- Maintenance: 900 mg (2 tablets) once daily.
⚠️ Administration: Must be taken WITH FOOD to ensure maximum absorption. Do not break or crush tablets (potential teratogen/carcinogen hazard).
- Hypersensitivity to valganciclovir, ganciclovir, or acyclovir.
- Severe bone marrow depression (Neutrophils < 500, Platelets < 25,000).
- Pregnancy and breastfeeding (FDA Category X).
Warning: Men should use barrier contraception during and for 90 days post-treatment.
Strict monitoring is required:
- Hematologic Toxicity: Severe neutropenia, anemia, and thrombocytopenia. Frequent Complete Blood Counts (CBC) are mandatory.
- Gastrointestinal: Diarrhea is the most common side effect. Nausea and vomiting may occur.
- Fever and fatigue.
What Customers Say
No reviews yet
Your review can be the first!